KAMIMURA Sachiyo

写真a

Affiliation

Faculty of Medicine College Hospital Pediatrics department

Title

Assistant Professor

External Link

 

Papers 【 display / non-display

  • Severe Traumatic Brain Injury in a Patient with von Willebrand Disease Type 2A Successfully Treated with Factor VIII/von Willebrand Factor Concentrates: A Case Report.

    Koroki T, Abe T, Kamimura S, Ochiai H

    The American journal of case reports   23   e936690   2022.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.12659/AJCR.936690

    PubMed

  • Successful treatment with rituximab for autoimmune cytopenia after autologous hematopoietic stem cell transplantation

    Kinoshita M., Yamada A., Saito Y., Kamimura S., Moritake H.

    Pediatrics international : official journal of the Japan Pediatric Society   64 ( 1 )   e14975   2022.1

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:Pediatrics international : official journal of the Japan Pediatric Society  

    DOI: 10.1111/ped.14975

    Scopus

    PubMed

  • Successful treatment of paraspinal/spinal epidural lymphoma by early intervention and local control with proton beam therapy

    Nagasawa S., Yamada A., Kinoshita M., Kamimura S., Moritake H.

    Pediatrics international : official journal of the Japan Pediatric Society   64 ( 1 )   e14970   2022.1

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:Pediatrics international : official journal of the Japan Pediatric Society  

    DOI: 10.1111/ped.14970

    Scopus

    PubMed

  • A Metastatic Neuroblastic Tumor in a 28-Month-Old Boy: Unusual Spontaneous Regression from Neuroblastoma to Ganglioneuroma?

    Yamada A., Kinoshita M., Kamimura S., Nakame K., Moritake H.

    Journal of Pediatric Hematology/Oncology   44 ( 2 )   E589 - E592   2021

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:Journal of Pediatric Hematology/Oncology  

    Neuroblastoma with bone metastasis is well known to have an extremely poor prognosis. We experienced the case of a patient with adrenal ganglioneuroblastoma (GNB) with metastases of subcutaneous nodules, a lymph node, and multiple bones. A pathologic examination of tumors from different sites revealed both GNB and ganglioneuroma. A genetic comparison between these tumors identified the same molecular signatures, suggesting the possibility of spontaneous differentiation in the remaining GNB. The patient has been healthy without aggressive chemotherapy, and the patient's pathologic urinary catecholamines normalized. Even if unusual, we have to recognize probable spontaneous differentiation from neuroblastoma to GNB and then to ganglioneuroma, even in sites of bone metastasis.

    DOI: 10.1097/MPH.0000000000002226

    Scopus

    PubMed

  • Pazopanib was effective for the treatment of refractory Ewing sarcoma with multiple pulmonary metastases

    Yokoyama Ryohei, Yamada Ai, Kinoshita Mariko, Sawa Daisuke, Saito Yusuke, Kamimura Sachiyo, Moritake Hiroshi

    The Japanese Journal of Pediatric Hematology / Oncology   58 ( 1 )   40 - 44   2021

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:The Japanese Society of Pediatric Hematology / Oncology  

    Ewing sarcoma (ES) is a malignant tumor originating from bone and soft tissue, and it frequently occurs in children and young adults. Although patients with localized ES normally have a disease-free survival rate of 70%, those with metastatic ES and who are refractory to primary chemotherapy have an extremely poor prognosis. We report on the case of a 19-year-old male diagnosed as having ES, who had an <i>EWSR1-FLI1</i> chimeric transcript originating from the right iliac bone. Chest computed tomography revealed multiple pulmonary metastases. He received VDC-IE consisting of vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide, followed by high-dose chemotherapy including busulfan and melphalan with autologous peripheral blood stem cell rescue and local radiotherapy. Afterwards, several lines of additional chemotherapy were performed; however, they failed to achieve a complete response. The administration of pazopanib induced a transient response, which allowed him to survive for an additional 7 months. Pazopanib is thus an available treatment option for refractory ES.

    DOI: 10.11412/jspho.58.40

    CiNii Research

display all >>

MISC 【 display / non-display